The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats.
Rolipram is a selective inhibitor of Type IV phosphodiesterase isozymes (PDE IV) which is often used as a baseline comparator for compounds in this class. To document the toxicological effects of rolipram, it was administered to female rats at 0, 10, 30 or 100 mg/kg/day orally for up to 2 weeks. One treatment-related death in the 100 mg/kg/day dose group was observed on day 3, and all rats at this dose level were considered moribund and euthanatized on day 5. Several clinical signs were observed in treated rats, including increased salivation, slight distention of the abdomen, emaciated appearance, and ataxia. After 14 days of treatment, the rats were necropsied and tissues examined microscopically. A number of compound-related histopathological changes were observed in rats receiving 30 or 100 mg/kg/day. Myocardial degeneration and necrosis, endocardial fibrosis, epicarditis, and arteritis/periarteritis of intramural and extramural coronary arteries were observed in the heart. A necrotizing vasculitis and inflammation were observed in the mesentery and interstitial areas of the liver, affecting medium-sized portal arteries and veins. Focal necrosis was also observed in the glandular mucosa of the stomach at these 2 dose levels. Other treatment-related effects included squamous hyperplasia and hyperkeratosis with or without ulceration in the nonglandular stomach of at least one animal from all treatment groups. Enlarged salivary glands were noted at necropsy in animals treated with 100 mg/kg/day, and this finding correlated microscopically with dilatation and degeneration of ducts and acini in the sublingual gland with secondary inflammation and edema. The results of this study demonstrate that rolipram, a selective inhibitor of the type IV class of PDE, can cause effects on the heart and vasculature of rats which heretofore have been ascribed only to selective inhibitors of the PDE III class of isozymes. Therefore, these organs should be closely examined in studies with other PDE IV inhibitors. In addition, the gastrointestinal tract and salivary glands were sites for rolipram-induced toxicity and may be targets of other PDE IV inhibitors.
Larson
J L
JL
Rhoune-Poulenc Rorer Research and Development, Department of Drug Safety, Collegeville, PA 19426-0107, USA.
Pino
M V
MV
Geiger
L E
LE
Simeone
C R
CR
D000818:Animals; D001808:Blood Vessels / Q000473:pathology; D001835:Body Weight / Q000187:drug effects; D004435:Eating / Q000187:drug effects; D005260:Female; D008099:Liver / Q000473:pathology; D009206:Myocardium / Q000473:pathology; D009336:Necrosis / Q000139:chemically induced / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000633:toxicity*; D011760:Pyrrolidinones / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D020889:Rolipram; D012469:Salivary Glands / Q000473:pathology; D015430:Weight Gain / Q000187:drug effects
D010726:Phosphodiesterase Inhibitors; D011760:Pyrrolidinones; D020889:Rolipram